Zeitschriftenaufsatz | 2025 Open Access

Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12

Autor:in
Troester, Selina; Eder, Thomas; Wukowits, Nadja; Piontek, Martin; Fernandez-Pernas, Pablo; Schmoellerl, Johannes; Haladik, Ben; Manhart, Gabriele; Allram, Melanie; Maurer-Granofszky, Margarita; Scheidegger, Nastassja; Nebral, Karin; Superti-Furga, Giulio; Meisel, Roland; Bornhauser, Beat; Valent, Peter; Dworzak, Michael N.; Zuber, Johannes; Boztug, Kaan; Grebien, Florian
Abstrakt
Nucleoporin 98 (NUP98) fusion oncoproteins are strong drivers of pediatric acute myeloid leukemia (AML) with poor prognosis. Here we show that NUP98 fusion-expressing AML harbors an epigenetic signature that is characterized by increased accessibility of hematopoietic stem cell genes and enrichment of activating histone marks. We employ an AML model for ligand-induced degradation of the NUP98::KDM5A fusion oncoprotein to identify epigenetic programs and transcriptional targets that are directly regulated by NUP98::KDM5A through CUT&Tag and nascent RNA-seq. Orthogonal genome-wide CRISPR/Cas9 screening identifies 12 direct NUP98::KDM5A target genes, which are essential for AML cell growth. Among these, we validate cyclin-dependent kinase 12 (CDK12) as a druggable vulnerability in NUP98::KDM5A-expressing AML. In line with its role in the transcription of DNA damage repair genes, small-molecule-mediated CDK12 inactivation causes increased DNA damage, leading to AML cell death. Altogether, we show that NUP98::KDM5A directly regulates a core set of essential target genes and reveal CDK12 as an actionable vulnerability in AML with oncogenic NUP98 fusions.
Schlagwörter
Humans; Nuclear Pore Complex Proteinsmetabolismgenetics; Oncogene Proteins, Fusionmetabolismgenetics; Leukemia, Myeloid, Acutegeneticsmetabolismpathology; Cyclin-Dependent Kinasesmetabolismgenetics; Epigenesis, Genetic; Cell Line, Tumor; Animals; Transcription, Genetic; Mice; Gene Expression Regulation, Leukemic; DNA Damage; CRISPR-Cas Systems; Retinoblastoma-Binding Protein 2
Dokumententyp
Originalarbeit
CC Lizenz
CCBY
Open Access Type
Gold

Weitere Details

Band
16
Nummer
1
Seitenanzahl
21